Between March 1987 and December 1988, 30 previously untreated patients with low-grade non-Hodgkin's lymphomas (NHL), according to the Kiel classification, were treated by a combination of therapy including cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP). Eighteen patients (60%) achieved a complete pathologic remission, and 8 patients (26.6%) had a partial response with a reduction of more than 50% of tumor-related manifestations. Four patients (13.4%) were primary resistant to CEOP. The overall survival was 96.6% with a median follow-up of 25 months from the diagnosis; none of the patients who achieved complete response relapsed at a median follow-up of 21 months from the completion of treatment. Clinical and hematologic toxicities were irrelevant. This regimen was effective in inducing a good remission rate of low-grade NHL, but a longer follow-up for definitive conclusions is warranted.
Get full access to this article
View all access options for this article.
References
1.
Al-IsmailS.A.D., WhittakerJ.A., GoughJ.: Combination chemotherapy including epirubicin for the management of non-Hcdgkin's lymphoma. Eur. J. Cancer Clin. Oncol., 23: 1379–1384, 1987.
2.
BonadonnaG.: Chemotherapy of malignant lymphomas. Semin. Oncol., 12: 1–14, 1985.
3.
CabanillasF., RodriguezV., FreireichE.J.: Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodg-kin's lymphoma: a prognostic factor comparison of two regimens. Med. Pediatr. Oncol., 4: 321–331, 1978.
4.
CarboneP.P., KaplanH.S., MusshoffK.: Report of Committee on Hodgkin's Disease Staging Classification. Cancer Res., 31: 1860–1861, 1971.
EliasL., PortlockC.S., RosenbergS.A.: Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP). Cancer, 42: 1705–1710, 1978.
7.
GanzinaF.: 4′-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat. Rev., 10: 1–22, 1983.
8.
GlickJ.H., BarnesJ.M., EzdinliE.Z.: Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood, 58: 920–925, 1981.
9.
HoppeR.T., KuslanP., KaplanH.S., RosenbergS.A., BrownB.W.: The treatment af advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single chemotherapy, combination chemotherapy, and whole body irradiation. Blood, 58: 592–598, 1981.
10.
HoppeR.T.: Treatment of low grade non-Hodgkin's lymphoma. In: Leucemia e Linfomi. Diagnosi e Terapia.VeronesiU., PolliE., BonadonnaG., SantoroA., EmanuelliH. (eds.), pp. 33–37. Casa Editrice Ambrosiana, Milano, 1985.
11.
LennertK., MohriN.: Histopathology and Diagnosis of non-Hodgkin's Lymphomas. Malignant Lymphomas Other Than Hodgkin's disease: Histology, Cytology, Ultrastructure, Immunology.LennertK. (ed.), pp. 111–469. Springer-Verlag, Berlin, Heidelberg, New York, 1978.
12.
MazzaP., LauriaF., GherlinzoniF., FiacchiniM., GalieniP., TuraS.: Non Hodgkin's lymphomas: prognostic feature of 55 patients treated with MEVAP chemotherapy. Haematologica, 69: 178–187, 1984.
13.
MazzaP., GherlinzoniF., ZinzaniP.L., TuraS., ZingaliG., A1 HabboubiN.: Epirubicin (E) in combination with cyclophosphamide (C), vincristine (V) and prednisolone (P) in all grades adult non-Hodgkin lymphomas (NHL). Proc. ASCO, 8: 263(1027), 1989.
MonfardiniS., TanciniG., De LenaM.: Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphoma. Med. Pediatr. Oncol., 3: 67–74, 1977.
16.
OkenM.M., CostelloW.G., JohnsonG.J., LenhardR.E., EzdinliE.Z., OrlowE., BarnesJ.M., BerardC.W., GlickJ.H.: The influence of histologic subtype on toxicity and response to chemotherapy in non-Hodgkin's lymphoma: an Eastern Cooperative Oncologic Group study utilizing the BCVP regimen. Cancer, 51: 1581–1586, 1983.
17.
PetersonB.A., FrizzeraG., AndersonJ.R.: Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisone, and bleomycin (CAVPB). Proc. ASCO, 4: C822, 1985.
18.
RosenbergS.A.: The low-grade non-Hodgkin's lymphomas: challenges and opportunities. J. Clin. Oncol., 3: 299–310, 1985.
19.
SkarinA.T., CanellosG.P., RosenthalD.S.: Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J. Clin. Oncol., 1: 91–98, 1983.
20.
YoungR.C., LongoD.L., GlatsteinE., IhdeD.C., JaffeE.S., De VitaV.T.Jr.: The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment. Semin. Hematol., 25: 11–16, 1988.
